The research alliance to create drug device and local medicines has been prolonged to five years.



CombinatoRx and Angiotech Pharmaceuticals have doubled the term of their R&D collaboration related to drug device and local medicines. Based on the successful advancement of a number of product candidates in preclinical models, the extended partnership to a total of five years has resulted in a $7-million payment to CombinatoRx due before October 3, 2007.


In October 2005, the companies entered into a research and license agreement that granted Angiotech an option to evaluate and exclusively license compounds it selected from the CombinatoRx clinical and preclinical pipeline and its bioinformatics database of synergistic combination pharmaceuticals.








This site uses Akismet to reduce spam. Learn how your comment data is processed.